ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2290

The 2011 Fibromyalgia (FM) Survey Criteria Are a Surrogate Measure of Pain Centralization

Steven E. Harte1, Daniel J. Clauw2, Andrew D. Clauw1, J. Ryan Scott1, Stephanie Moser1 and Chad Brummett2, 1Department of Anesthesiology, University of Michigan, Ann Arbor, MI, 2Anesthesiology, University of Michigan, Ann Arbor, MI

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Chronic pain, fibromyalgia and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The 2011 FM Survey Criteria can either be used as a dichotomous measure to diagnose an individual with FM, or in a continuous manner to determine the degree of “fibromyalgianess” an individual is experiencing.  Used in this latter manner, studies have suggested that this measure is predictive of decreased responsiveness to opioids in the perioperative period, and decreased improvement in pain following knee and hip arthroplasty.  This has led us and others to suggest that this measure is a surrogate measure of the central sensitization an individual is experiencing.  However, a critical portion of the central sensitization construct is that an individual experiences pain augmentation or amplification, measured either by quantitative sensory testing (QST) or functional neuroimaging.  This study examines the relationship between the FM Survey Criteria and QST findings in a cohort of individuals with osteoarthritis.

Methods: 101 individuals with osteoarthritis (ages 41 – 85, 45 male, 56 female) awaiting joint arthroplasty had a battery of self-report measures including the 2011 FM Survey Criteria.  These individuals also underwent an extensive QST battery including mechanical pain threshold and tolerance, temporal summation, and conditioned pain modulation – at both the affected knee, as well as several neutral sites (including thumb and trapezius).  The cohort of 101 individuals was then split into three tertiles of FM scores, from 0-3 (n = 37), 4-7 (n = 34), and 8 or greater (n = 30).  ANOVA was performed comparing mean QST values in each tertile.

Results: For nearly all static QST variables, there was a stepwise change in the hypothesized direction between QST measures and FM tertiles.  Most but not all of these changes reached statistical significance.  The three tertiles showed a similar stepwise increase in pain intensity, even though the FM criteria do not assess pain intensity, just distribution.

Conclusion: This is the first study to demonstrate that the 2011 FM Survey Criteria show a strong relationship to QST measures in a cohort of individuals with knee osteoarthritis.  This provides further evidence that this simple to administer measure may serve as a surrogate measure of pain centralization in individuals with chronic pain states.


Disclosure: S. E. Harte, MAST Device, 4,Cerephex, 5,Analgesic Solutions, 5,Merck, 5,Regeneron, 5,deCode Genetics, 5; D. J. Clauw, Abbott Laboratories, 5,Cerephex, 5,Eli Lilly and Company, 5,Forrest Laboratories, 5,Johnson & Johnson, 5,Merck Pharmaceuticals, 5,Pfizer Inc, 5,Purdue Pharma L.P., 5,Samumed, 5,Theravance, 5,Tonix, 5,UCB, 5,Zynerba, 5,Abbott Laboratories, 5,Cerephex, 5,Eli Lilly and Company, 5,Forest Laboratories, 5,Johnson & Johnson, 5,Merck Pharmaceuticals, 5,Pfizer Inc, 6,Purdue Pharma L.P., 6,Samumed, 5,Theravance, 5,Tonix, 5,UCB, 5,Zynerba, 5; A. D. Clauw, None; J. R. Scott, None; S. Moser, None; C. Brummett, Tonix Pharmaceuticals, 5.

To cite this abstract in AMA style:

Harte SE, Clauw DJ, Clauw AD, Scott JR, Moser S, Brummett C. The 2011 Fibromyalgia (FM) Survey Criteria Are a Surrogate Measure of Pain Centralization [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-2011-fibromyalgia-fm-survey-criteria-are-a-surrogate-measure-of-pain-centralization/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-2011-fibromyalgia-fm-survey-criteria-are-a-surrogate-measure-of-pain-centralization/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology